Healthcare / Drug Manufacturers - Specialty & GenericNSE
$22.35
+0.60 (+2.90%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-717.0M · quality 58.3/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
60/100
B
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$8.5B
P/E
10.8x
↓EV/EBITDA
7.4x
↓ROE
11.6%
↑Gross Margin
46.8%
↓Debt/Equity
0.24
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+24.9%
FCF CAGR
—
FCF margin
-3.4%
FCF / Net income
-0.24x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $4.88B · net income $695.6M · FCF $-164.0M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $4.88B | $4.88B | $3.99B | $3.02B | $2.50B |
| Net Income | $695.6M | $695.6M | $571.8M | $435.4M | $400.4M |
| EBITDA | $1.19B | $1.19B | $858.3M | $642.0M | $551.7M |
| EPS | 2.06 | 2.06 | 1.54 | 1.42 | 1.54 |
| Gross Margin | 46.8% | 46.8% | 43.7% | 46.4% | 45.0% |
| Operating Margin | 17.6% | 17.6% | 16.5% | 17.4% | 20.1% |
| Net Margin | 14.2% | 14.2% | 14.3% | 14.4% | 16.0% |
| Balance Sheet | |||||
| Debt/Equity | 0.24 | 0.24 | 0.35 | 0.26 | 0.15 |
| Current Ratio | 1.44 | 1.44 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-164.0M | $-164.0M | $-723.0M | $-717.0M | $-184.8M |
| Returns | |||||
| ROE | 11.6% | 11.6% | 13.3% | 16.2% | 17.6% |
| Valuation | |||||
| P/E | 10.85 | 10.85 | 45.42 | 16.83 | 21.19 |
| EV/EBITDA | 7.39 | 7.39 | 31.91 | 12.30 | 15.49 |
| P/B | 1.25 | 1.25 | 6.06 | 2.74 | 3.73 |
| Growth & Yield | |||||
| Revenue Growth | 22.4% | 22.4% | 32.1% | 20.7% | — |
| EPS Growth | 33.8% | 33.8% | 8.5% | -8.0% | — |
| Dividend Yield | 0.5% | 0.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
-1.3%
EPS terminal req.
$1.98
Spread vs growth
35.0%
5Y implied EPS CAGR
3.1%
EPS terminal req.
$2.40
Spread vs growth
30.7%
10Y implied EPS CAGR
6.5%
EPS terminal req.
$3.86
Spread vs growth
27.3%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-50.6%
Start / end P/E
28.3x → 10.3x
EPS bridge
1.54 → 2.06
Residual
-21.4%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.